

Keep your patients legs looking great with ASCLERA

ASCLERA® (polidocanol) Injection is the **ONLY** **FDA-approved** liquid polidocanol 0.5% and 1% formulations indicated to sclerose uncomplicated spider veins (varicose veins \leq 1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity.¹

A
S
C
L
E
R
A



Ensure your patients are
equipped to care for their legs
once they leave your office

IN CLINIC¹

After the needle has been removed and the injection site has been covered, apply compression in the form of a stocking or bandage.

Tell them to walk for 15 to 20 minutes immediately after the procedure and daily for the next few days.

COMPRESSION¹

Advise patient to maintain 24 hr compression continuously after treatment.

Spider veins: 2 to 3 days

Reticular veins: 5 to 7 days

For extensive varicosities, longer compression may be needed (additional 2-3 weeks during the daytime). Compression stockings or support hose should be knee or thigh high depending upon the area treated in order to provide adequate coverage.

POST-TREATMENT¹

For 2 to 3 days following treatment, advise to avoid heavy exercise, sunbathing, long plane flights, and hot baths or sauna.

Small intravaricose thrombi (trapped blood or retained coagulum) that develop may be removed by microthrombectomy (puncture aspiration or extraction).

ASCLERA is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. In clinical studies, the following adverse reactions were observed after using ASCLERA and were more common with ASCLERA than placebo: injection site hematoma, injection site irritation, injection site discoloration, injection site pain, injection site itching, injection site warmth, neovascularization, injection site clotting.

Please consult the package insert for full prescribing information including warnings and precautions, available on request by calling Methapharm Medical Information at 1-866-701-4636, or to view and download at www.ASCLERA.com.

To report SUSPECTED ADVERSE REACTIONS, contact Methapharm Medical Information at 1-866-701-4636, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.


For all other ASCLERA inquiries please call 1-833-766-8346.



Interested in ASCLERA In Your Practice?
For more information, visit www.ASCLERA.com

Distributed by Methapharm, Inc. Copyright © 2025 Methapharm, Inc.
All rights reserved. ASCLERA® is a registered trademark of Chemische
Fabrik Kreussler & Co. GmbH
ASC-USEN-VDAR1-1225

methapharm
Specialty Pharmaceuticals



Asc for
ASCLERA®
(Polidocanol) Injection

ASCLERA®

(Polidocanol) Injection

Simple procedure
for sustained results

Uncomplicated spider vein treatment
(≤ 1 mm) patient treated with 0.5% ASCLERA



Uncomplicated reticular vein treatment
(1-3 mm) patient treated with 1% ASCLERA



Improvement 18 weeks
after last treatment

Give your patients the treatment success their legs deserve

ASCLERA was evaluated in a multicenter, randomized, double-blind, placebo- and comparator-controlled trial (EASI-study). Primary endpoint was improvement of veins judged by a blinded panel.²




of patients treated with ASCLERA showed good or complete treatment success as rated by physicians.²

ASCLERA treatment results were statistically significant vs placebo (p <0.0001) for the primary efficacy criterion of "improvement of veins".²

EASI Study: ASCLERA (polidocanol) vs STS^{2†}

A prospective, multicenter, randomized, double-blind, placebo- and comparator-controlled study of 338 patients that received sclerotherapy with either 0.5% or 1% ASCLERA (polidocanol), or 1% STS, or placebo (0.9% isotonic saline).



†At 12 and 26 weeks after last injection, patients were given digital images of their baseline spider and reticular (small varicose) veins and asked to rate their satisfaction using a verbal rating scale (1 = very unsatisfied, 2 = somewhat unsatisfied, 3 = slight satisfied, 4 = satisfied, 5 = very satisfied).

Choose the ASCLERA strength for best treatment results

ADMINISTRATION¹

Use 0.1 mL to 0.3 mL for each injection with a maximum volume of 10 mL per treatment session.

Solution strength depends on the size and extent of the veins. Extensive varicosities may require multiple treatment sessions separated by 1-2 weeks.

ASCLERA IS AVAILABLE IN TWO STRENGTHS:

ASCLERA 0.5% is indicated for **Spider Veins**
(veins ≤ 1 mm in diameter).



ASCLERA 1% is indicated for **Reticular Veins**
(veins 1 mm to 3 mm in diameter).

Each box of ASCLERA has 5 glass ampules, with each glass ampule containing 2 mL of ASCLERA

Product Description	Order Number	NDC
ASCLERA (polidocanol) Injection 0.5% (10 mg per 2 mL ampule)	5000038	67850-140-05
ASCLERA (polidocanol) Injection 1.0% (20 mg per 2 mL ampule)	5000039	67850-141-05

Order online or by contacting our dedicated Customer Support Team by email ASCLERA@methapharm.com or phone 1-833-766-8346 (VEIN).

References:

1) ASCLERA® Full Prescribing Information. Methapharm, Inc.

2) Rabe E, Schliephake D, Otto J, Breu FX, et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). *Phlebology* 2010;25:124-31.